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Abstract
Alzheimer’s disease is characterised by the degeneration of selected populations of nerve cells that develop filamentous
inclusions prior to degeneration. The neuronal inclusions of Alzheimer’s disease are made of the microtubule-associated
protein tau, in a hyperphosphorylated state. Abundant filamentous tau inclusions are not limited to Alzheimer’s disease.
They are the defining neuropathological characteristic of frontotemporal dementias, such as Pick’s disease, and of
progressive supranuclear palsy and corticobasal degeneration. The discovery of mutations in the tau gene in familial
frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) has provided a direct link between tau
dysfunction and dementing disease. Known mutations produce either a reduced ability of tau to interact with microtubules,
or an overproduction of tau isoforms with four microtubule-binding repeats. This leads in turn to the assembly of tau into
filaments similar or identical to those found in Alzheimer’s disease brain. Several missense mutations also have a stimulatory
effect on heparin-induced tau filament formation. Assembly of tau into filaments may be the gain of toxic function that is
believed to underlie the demise of affected brain cells. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Frontotemporal dementias are neurodegenerative
diseases that constitute a common cause of dementia.
They are characterised by a striking degeneration of
the frontal and temporal lobes of the cerebral cortex,
which is sometimes unilateral [1]. In many cases, ad-
ditional degenerative changes are observed in sub-
cortical brain regions, such as the substantia nigra.
Onset of frontotemporal dementia is usually before
65 years of age and the most common clinical man-
ifestation is a profound change in personality and
social behaviour, with a relative preservation of
memory until later stages of the disease [1,2]. Most
cases of frontotemporal dementia are sporadic, with
a proportion being inherited. In a population study
from the Netherlands, 38% of cases of frontotempo-
ral dementia were found to be familial [3].
In 1994, linkage of a familial disease called disin-
hibition-dementia-parkinsonism-amyotrophy com-
plex (DDPAC) to chromosome 17q21^22 was de-
scribed [4]. It was followed by reports showing
linkage of a number of inherited dementing diseases
with preceding personality changes to the same re-
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gion of chromosome 17 [5^13]. In 1996, a consensus
conference grouped these diseases under the heading
of ‘frontotemporal dementia and parkinsonism
linked to chromosome 17’ (FTDP-17) [14].
Neuropathologically, some of these familial fron-
totemporal dementias had been shown to be charac-
terised by an abundant ¢lamentous pathology made
of hyperphosphorylated tau protein, similar to that
observed in Alzheimer’s disease [15^17]. Together
with the fact that the tau gene maps to the region
of the critical interval on chromosome 17, this made
tau a strong candidate gene for the FTDP-17 locus.
The discovery of over a dozen di¡erent exonic and
intronic mutations in the tau gene in more than 40
families with frontotemporal dementia has now
shown that the tau gene is indeed the FTDP-17 locus
[18^29]. It follows that tau dysfunction causes neuro-
degeneration. This has implications for other diseases
with a ¢lamentous tau pathology, such as Alzheim-
er’s disease, Pick’s disease, progressive supranuclear
palsy and corticobasal degeneration.
2. Tau protein in normal brain
Multiple tau isoforms are produced from a single
gene by alternative mRNA splicing. The six tau iso-
forms expressed in adult human brain range from
352 to 441 amino acids in length and di¡er from
each other by the presence or absence of three exons
(Fig. 1a) [30^32]. Eleven exons (numbered 1^13)
make up the longest human brain tau isoform, with
exons 2, 3 and 10 being subject to alternative mRNA
splicing [30^33]. The most striking feature of the tau
sequences is the presence of three or four tandem
repeats of 31 or 32 amino acids located in the car-
boxy-terminal half, each containing a characteristic
Pro-Gly-Gly-Gly motif. The extra repeat of 31 ami-
no acids (encoded by exon 10) in the isoforms with
four repeats is inserted within the ¢rst repeat of the
isoforms with three repeats in a way that preserves
the periodic pattern [31]. Besides being distinguished
by the presence of three or four tandem repeats,
some tau isoforms contain 29 (encoded by exon 2)
or 58 (encoded by exons 2 and 3) amino acid inserts
located near the amino-terminus [32,33]. In immature
human brain, only the shortest tau isoform with
three repeats is expressed [31]. The developmental
shift of human tau bands from a simple foetal to a
more complex adult pattern thus involves the transi-
tion from the expression of the isoform with three
repeats containing no amino-terminal inserts, to the
expression of all six isoforms. Tau isoforms with a
large additional insert in the amino-terminal half (en-
coded by exon 4A) have been described in the pe-
ripheral nervous system [34,35]).
Experiments with synthetic peptides and with tau
proteins produced by expression in Escherichia coli
have shown that the carboxy-terminal repeats and
some adjoining sequences constitute microtubule-
binding domains [36^40] Microtubules assembled in
the presence of tau show arms projecting from the
surface [41]. Tau thus consists of a carboxy-terminal
microtubule-binding domain and an amino-terminal
projection domain, with the latter determining the
spacing between adjacent microtubules [42]. Re-
combinant tau isoforms with four repeats promote
faster microtubule assembly than those with three
repeats, as might be expected if one tau molecule
links a number of tubulin subunits [43].
When individual tau isoforms that have been ex-
pressed in E. coli are mixed together, they give a
characteristic set of six bands, ranging from 48 to
67 kDa in apparent molecular mass [43]. Comparison
of the pattern of recombinant tau isoforms with that
of native tau shows that the four major tau isoforms
in adult human brain correspond to isoforms with
three and four repeats without amino-terminal in-
serts and to isoforms with three and four repeats
containing the ¢rst amino-terminal insert of 29 ami-
no acids. Isoforms with three and four repeats with
the 58 amino acid amino-terminal insert are also
found, albeit at lower levels. These ¢ndings establish
that the six isoforms identi¢ed by cDNA cloning
account for the tau isoforms in adult human brain,
where similar levels of three-repeat and four-repeat
isoforms are the norm. There exist true species di¡er-
ences in the expression of tau isoforms. Immature
rodent brain expresses the shortest three-repeat tau
isoform, like the immature human brain. However,
unlike adult human brain, adult rodent brain only
expresses three tau isoforms, each with four micro-
tubule-binding repeats [44,45].
Tau is an abundant protein in both central and
peripheral nervous systems. In brain, it is found pre-
dominantly in nerve cells, with lower levels in some
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glial cells. Within nerve cells, it is found mainly in
axons [46]. The major known physiological function
of tau derives from its ability to promote microtu-
bule assembly and to bind to microtubules, which are
thus stabilised. Inactivation of the tau gene by ho-
mologous recombination leads to no overt pheno-
type, indicating that tau is not an essential protein
[47].
Tau is a phosphoprotein and phosphorylation is
also developmentally regulated [48,49]. Thus, tau
from developing brain is phosphorylated more than
tau from adult brain, implying selective dephosphor-
ylation of the shortest tau isoform during brain mat-
uration. Tau from developing brain is phosphorylat-
ed at 15 known sites in the shortest isoform, whereas
tau from adult brain is phosphorylated at at least
nine sites in the six isoforms [49]. With the exception
of S262, which is located at the beginning of the ¢rst
repeat, all the known phosphorylation sites in tau are
located outside the microtubule-binding repeat re-
gion. Many of these sites are serine or threonine
residues that are followed by a proline. Accordingly,
mitogen-activated protein kinase, glycogen synthase
kinase-3, neuronal cdc2-like kinase and stress-acti-
vated protein kinases phosphorylate tau at many of
these sites in vitro [50^53]. Studies using lithium
chloride as a speci¢c inhibitor have strongly sug-
gested that glycogen synthase kinase-3 is a tau kinase
in brain [54,55]. Tau phosphorylation by a number
of protein kinases is markedly stimulated by sulfated
Fig. 1. Mutations in the tau gene in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). (a) Schematic
diagram of the six tau isoforms (A^F) that are expressed in adult human brain. Alternatively spliced exons are shown in red (exon 2),
green (exon 3) and yellow (exon 10). Black bars indicate the microtubule-binding repeats. Seven missense mutations and one deletion
mutation in the coding region are shown. They a¡ect all six tau isoforms, with the exception of N279K, vK280, P301L, P301S and
S305N which a¡ect only tau isoforms with four microtubule-binding repeats. Amino acid numbering corresponds to the 441-residue
isoform of human brain tau. (b) Stem-loop structure in the pre-mRNA at the boundary between exon 10 and the intron following
exon 10. Nucleotides 35 to +19 are shown, with the ¢rst nucleotide of the splice-donor site taken as +1. The S305N mutation at po-
sition 31 and the intronic mutations (at positions +3, +13, +14 and +16) are indicated. Exon sequences are shown in capital and in-
tron sequences in lower-case letters.
Fig. 2. E¡ects of coding region mutations in tau on the ability
of four-repeat htau46 (412 amino acid isoform of human tau)
to promote microtubule assembly. Polymerisation of tubulin in-
duced by wild-type htau46 and six mutant proteins (G272V,
vK280, P301L, P301S, V337M, R406W), as measured over
time by turbidimetry.
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Fig. 3. E¡ects of coding region mutations in tau on heparin-induced assembly of tau ¢laments. Representative ¢elds of ¢laments as-
sembled from various wild-type and mutant tau proteins. A^E, Four-repeat tau (htau46). F^H, Three-repeat tau (htau37). (A) Wild-
type; (B) P301S; (C) P301L; (D) G272V; (E) R406W; (F) Wild-type; (G) G272V; (H) V337M. Scale bar: 200 nm.
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glycosaminoglycans, such as heparin and heparan
sulfate [56^60].
Of the major phosphatase activities in brain, tau is
dephosphorylated predominantly by the trimeric
form of phosphatase 2A [61,62]. The use of SV40
small t as a speci¢c inhibitor has shown that PP2A
controls the phosphorylation state of tau in vivo [63].
Phosphorylation negatively regulates the function of
tau [64,65]. Thus, the more phosphorylated tau is,
the less able it is to bind to microtubules and to
promote microtubule assembly. Hyperphosphoryla-
tion is an invariant feature of the ¢lamentous tau
deposits that characterise a number of neurodegener-
ative diseases [66].
3. Tau mutations in FTDP-17
Tau mutations in FTDP-17 are either missense or
deletion mutations in the coding region, or intronic
mutations located close to the splice-donor site of the
intron following the alternatively spliced exon 10
[18^20] (Fig. 1). Missense mutations are located in
the microtubule-binding repeat region or close to it.
Mutations in exon 9 (G272V), exon 12 (V337M) and
exon 13 (R406W) a¡ect all six tau isoforms (Fig. 1a)
[18,19]. By contrast, mutations in exon 10 (N279K,
vK280, P301L, P301S and S305N) only a¡ect tau
isoforms with four microtubule-binding repeats or
their expression (Fig. 1a) [18,19,21^24,27^29]. Most
missense mutations reduce the ability of tau to inter-
act with microtubules, as re£ected by a marked re-
duction in the ability of mutant tau to promote mi-
crotubule assembly (Fig. 2) [23,29,67^69]. Mutations
in exon 10 (vK280, P301L and P301S) produce the
largest e¡ects, with intermediate reductions for mu-
tations in exons 9 (G272V) and 12 (V337M), and a
smaller reduction for the R406W mutation in exon
13 [23,29,67]. Moreover, a number of missense mu-
tations have a direct stimulatory e¡ect on heparin-
induced assembly of tau into ¢laments (Fig. 3)
[70,71]. This e¡ect is particularly marked for the
P301L and P301S mutations, with smaller e¡ects
for the G272V and V337M mutations. A study using
synthetic peptides derived from each of the four mi-
crotubule-binding repeats of tau has shown increased
heparin-induced ¢lament formation for the P301L
mutation in the second repeat [72].
Intronic mutations are located at positions +3,
+13, +14 and +16 of the intron following exon 10,
with the ¢rst nucleotide of the splice-donor site taken
as +1 (Fig. 1b) [18,20,25,26]. Secondary structure
predictions have suggested the presence of an RNA
stem-loop structure at the exon 10-intron boundary
that is disrupted by the intronic mutations [18,20]. In
addition, the +3 mutation is predicted to lead to
increased binding of U1snRNA to the 5P splice site
[20]. Exon trapping experiments have shown that in-
tronic mutations lead to increased splicing in of exon
10 [19,73]. Increased production of transcripts encod-
ing exon 10 has also been demonstrated in brain
tissue from patients with tau intronic mutations
[19,73]. This is in turn re£ected by a change in the
Fig. 4. Soluble tau from familial subcortical gliosis (PSG) brain
(with the +16 intronic mutation in the tau gene). Comparison
with soluble tau from control brain. (A) Immunoblots of de-
phosphorylated soluble tau protein extracted from the frontal
cortex of three control subjects (lanes 1^3) and three a¡ected
individuals from the PSG-1 kindred (lanes 4^6). Arrows (lanes
1 and 6) indicate the positions of the three tau isoforms with
four repeats; the other isoforms have three repeats each. (B)
Quantitation of the ratio of four-repeat to three-repeat (4R/3R)
tau isoforms in frontal cortex from control and familial PSG
brains. Results are expressed as means þ S.D. (n = 3).
*P6 0.0001.
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ratio of three-repeat to four-repeat tau isoforms, re-
sulting in a net overproduction of four-repeat iso-
forms (Fig. 4) [20,26,68,73].
The proposed existence of a stem-loop structure at
the boundary between exon 10 and the intron follow-
ing exon 10 [19,20] has received strong support from
the determination of the three-dimensional structure
of a 25-nucleotide-long RNA (extending from posi-
tions 35 to +19) by NMR spectroscopy (Fig. 1b)
[73]. The stem of this exon 10 regulatory element
RNA consists of a single stable G-C base pair which
is separated from a double helix of six base pairs by
an unpaired adenine. The apical loop consists of six
nucleotides that adopt multiple conformations in
rapid exchange. The structure di¡ers in several re-
spects from the two proposed representations of the
stem-loop [19,20]. Known intronic mutations are lo-
cated in the upper part of the stem of the tau exon 10
regulatory element. All four mutations reduce the
thermodynamic stability of the stem-loop structure,
but to various extents [73]. The largest drop in melt-
ing temperature was observed for the +3 mutation.
The +14 mutation also produced a large reduction in
melting temperature, whereas the e¡ects of the +13
and +16 mutations were smaller. The di¡erential re-
ductions in stem-loop stability resulting from the in-
tronic FTDP-17 mutations were re£ected in exon
trapping experiments [73]. The +3 mutation pro-
duced the largest increase in the splicing in of exon
10, followed by the +14 mutation, with smaller in-
creases for the +13 and +16 mutations.
The emerging picture is one of missense mutations
that lead to a reduced ability of tau to interact with
microtubules and to a stimulatory e¡ect on tau ¢la-
ment assembly, and of intronic mutations whose pri-
mary e¡ects are at the RNA level, resulting in an
overproduction of tau isoforms with four microtu-
bule-binding repeats [74]. However, two missense
mutations in exon 10 deviate from this rule in that
they do not lead to a reduction in the ability of tau
to promote microtubule assembly [68,75]. Instead,
they increase splicing in of exon 10, as is the case
of the intronic mutations. The N279K mutation
(AAT to AAG) in tau creates a purine-rich splice
enhancer sequence that explains its e¡ects on exon
trapping and soluble four-repeat tau in brain
[22,68,75]. The S305N mutation (AGT to AAT) in
tau changes the last amino acid in exon 10 [24]. This
sequence forms part of the predicted stem-loop struc-
ture, where the mutation produces a G to A transi-
tion at position 31. It is therefore not surprising that
the S305N mutation leads to a reduction in the ther-
modynamic stability of the stem-loop structure and
to a marked increase in the splicing in of exon 10
[73,75]. Like the +3 mutation, the 31 mutation is
also expected to lead to increased binding of
U1snRNA to the 5P splice site. Besides mutations
in the intron following exon 10, additional pathogen-
ic mutations may exist in other introns of the tau
gene. Thus, a G to A transition at position +33 of
the intron following exon 9 has been described in a
patient with familial frontotemporal dementia [23]. It
disrupts one of several (A/T)GGG repeats that may
play a role in the regulation of the alternative splic-
ing of exon 10.
4. Neuropathology of FTDP-17
All cases of FTDP-17 examined to date have
shown the presence of an abundant ¢lamentous
pathology made of hyperphosphorylated tau protein
[17,66,74]. Strikingly, the morphologies of tau ¢la-
ments and their isoform compositions appear to be
Table 1
Tau mutations, isoforms and ¢laments in FTDP-17
Tau mutation Soluble tau Filamentous tau Tau ¢laments
P301L (exon 10) Normal ratio of 3- to 4-repeat
isoforms (4-repeat isoforms mutated)
4-Repeat isoforms. Small
amount of 3-repeat isoform
Narrow twisted ribbons in neurones
and glia. Rope-like ¢laments
Intron following exon
10. N279K (exon 10)
Abnormal preponderance of 4- over
3-repeat isoforms
4-Repeat isoforms Wide twisted ribbons in neurones and
glia
V337M (exon 12).
R406W (exon 13)
Normal ratio of 3- to 4-repeat
isoforms (all isoforms mutated)
All 6 isoforms Paired helical ¢laments and straight
¢laments in neurones
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determined by whether tau mutations a¡ect mRNA
splicing of exon 10, or whether they are missense
mutations located inside or outside exon 10 (Table
1, Fig. 5).
Mutations in tau that a¡ect splicing of exon 10
lead to the formation of wide twisted ribbon-like
¢laments which contain only four-repeat tau iso-
forms [16,26]. This has been shown in familial multi-
ple system tauopathy with presenile dementia
(MSTD) with the +3 intronic mutation and in fam-
ilial progressive subcortical gliosis with the +16 mu-
tation (Fig. 5). Similar results have been obtained in
pallido-ponto-nigral degeneration with the N279K
mutation in exon 10 whose primary e¡ect is at the
RNA level [22,68,75]. The same may be true of the
family with the S305N mutation in exon 10 whose
primary e¡ect is also at the RNA level [24,75]. In all
these FTDP-17 families, the tau pathology is wide-
spread and present in both nerve cells and glial cells,
with an abundant glial component.
Mutations in exon 10 of tau lead to the formation
of narrow twisted ribbons that contain four-repeat
tau isoforms, with a small amount of the most abun-
dant three-repeat isoform (Fig. 5). This has been
shown in Dutch family 1 and in an American family,
both with the P301L mutation [27,76]. Based on elec-
tron microscopy of tissue sections, the same also ap-
pears to be true of the family with the P301S
mutation [29]. At present, no neuropathological
information is available for the family with the
vK280 mutation in exon 10 [23]. The P301L,
P301S and vK280 mutations all lead to a markedly
reduced ability of tau to promote microtubule assem-
bly [23,29,67]. This is not the case of the N279K and
S305N mutations that increase splicing in of exon 10,
and whose tau pathologies are therefore like those in
families with intronic mutations [22,24]. In brain tis-
sue from individuals with the P301L and P301S mu-
tations, tau pathology is widespread and present in
both nerve cells and glial cells [27,29,76]. When com-
pared with mutations that a¡ect the splicing in of
exon 10, the glial component is less pronounced.
Coding region mutations located outside exon 10
of tau lead to the formation of PHFs and SFs that
contain all six tau isoforms (Fig. 5) [15,77]. This has
been shown for Seattle family A with the V337M
mutation in exon 12 and for a family with the
R406W mutation in exon 13. In Seattle family A,
the morphologies of tau ¢laments have been found
to be indistinguishable from those of Alzheimer’s
disease [15]. In these families, tau pathology is found
in nerve cells, without a signi¢cant glial component.
5. Pathogenesis of FTDP-17
The pathway leading from a mutation in the tau
gene to neurodegeneration is unknown. The likely
primary e¡ect of most missense mutations is a re-
duced ability of mutant tau to interact with micro-
tubules [67,68]. It may be equivalent to a partial loss
of function, with resultant microtubule destabilisa-
tion and deleterious e¡ects on cellular processes,
such as rapid axonal transport. However, in the
case of the intronic mutations and the N279K and
S305N missense mutations in exon 10, this appears
Fig. 5. Tau ¢laments in FTDP-17. Dutch family 1 (with the
P301L mutation in exon 10) is characterised by the presence of
narrow twisted ribbons (A) and occasional rope-like ¢laments
(B). The tau pathology is both neuronal and glial. Familial
multiple system tauopathy with presenile dementia (with the +3
intronic mutation) and familial progressive subcortical gliosis
(with the +16 intronic mutation) are characterised by wide
twisted ribbons (C), which might be formed by two copies of
the narrow twisted ribbons joined across the central axis. The
tau pathology is both neuronal and glial. Seattle family A (with
the V337M mutation in exon 12) and a family with the R406W
mutation in exon 13 are characterised by the presence of paired
helical (D) and straight (E) ¢laments, like those found in Alz-
heimer’s disease brain. The tau pathology is largely neuronal.
Scale bar: 100 nm.
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unlikely. The net e¡ect of these mutations is in-
creased splicing in of exon 10, leading to a change
in the ratio of three-repeat to four-repeat tau iso-
forms, and resulting in the overproduction of four-
repeat isoforms [19,20,22,78]. Moreover, missense
mutations in exon 10 will only a¡ect 20^25% of tau
molecules, with 75^80% of tau being normal.
It is possible, however, that a correct ratio of wild-
type three-repeat to four-repeat tau is essential for
the normal function of tau in human brain. An alter-
native hypothesis is that a partial loss of function of
tau is necessary for setting in motion the mechanisms
that ultimately lead to ¢lament assembly. Earlier
work had suggested that three-repeat and four-repeat
tau isoforms may bind to di¡erent sites on micro-
tubules [79]. Overproduction of tau isoforms with
four repeats may result in an excess of tau over avail-
able binding sites on microtubules, thus creating a
gain of toxic function similar to that of most mis-
sense mutations, with unbound excess tau available
for assembly into ¢laments.
Where studied, pathological tau from FTDP-17
brain is hyperphosphorylated [66,74]. As known mu-
tations in tau do not create additional phosphory-
lation sites (with the possible exception of the
P301S mutation), hyperphosphorylation of tau
must be an event downstream of the primary e¡ects
of the mutations and may be a consequence of the
partial loss of function. It probably reinforces the
e¡ects of the mutations, since it is well established
that hyperphosphorylated tau is unable to bind to
microtubules [64,65]. At present, there is no experi-
mental evidence linking hyperphosphorylation of tau
to ¢lament assembly, and it is unclear whether hyper-
phosphorylation is either necessary or su⁄cient for
assembly. Thus, assembly of full-length hyperphos-
phorylated tau into ¢laments has not been observed.
In fact, experimental studies in vitro have shown that
interactions between tau and negatively charged sug-
ar polymers, such as sulfated glycosaminoglycans
and RNA, lead to rapid assembly into twisted and
straight ¢laments in a phosphorylation-independent
manner [59,80^83]. These studies have provided a
¢rst robust method for the assembly of synthetic ¢l-
aments from full-length tau protein. They have also
permitted studies investigating the e¡ects of missense
mutations in tau on ¢lament assembly, resulting in
the demonstration of marked stimulatory e¡ects of
some mutations, such as G272V, P301L and P301S
[70,71].
The mechanisms that lead to assembly of tau into
¢laments in brain remain to be discovered. It is pos-
sible that a reduced ability to interact with micro-
tubules, which could have several di¡erent causes,
is a necessary step for ¢lament assembly. Assembly
is an energetically unfavourable, nucleation-depen-
dent process that requires a critical concentration
of tau [80,83]. Many cells may have levels of tau
below the critical concentration. Other cells may
have e¡ective mechanisms for preventing the forma-
tion of tau nuclei, or may be able to degrade them
once they have formed. Insu⁄cient protective mech-
anisms and high tau concentrations may underlie the
selective degeneration of nerve cells and glial cells,
which is especially striking in FTDP-17, with the
characteristic, sometimes unilateral, razor-sharp de-
marcations between a¡ected and una¡ected areas in
cerebral cortex.
The precise signi¢cance of the di¡erent ¢lament
morphologies observed in FTDP-17 is not clear. It
is known that the repeat region of tau forms the
densely packed core of PHFs and SFs, with the ami-
no- and carboxy-terminal parts of the molecule
forming a proteolytically sensitive coat [84^86].
Also, for ¢laments assembled in vitro in the presence
of sulfated glycosaminoglycans, the morphology of
the ¢laments depends on the number of repeats in
the tau isoform used [80]. Thus, mutations in the
repeat region or a change in the relative amounts
of three- and four-repeat isoforms could well in£u-
ence ¢lament morphology. Treatment of PHFs with
acid leads to untwisted, ribbon-like ¢laments like
those seen in familial MSTD [87], suggesting a close
similarity in packing of tau molecules in the various
structures. The most important aspect may be the
extended ¢lamentous nature of the assemblies and
the deleterious e¡ects that this has on intracellular
processes, rather than the detailed morphology of the
di¡erent ¢laments.
6. Implications for Alzheimer’s disease and other
tauopathies
A major implication deriving from the work on
FTDP-17 is that a normal ratio of functional tau
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isoforms to microtubules appears to be essential for
preventing neurodegeneration. This ¢nely tuned bal-
ance may be very sensitive to disruption, in line with
the fact that a large percentage of the general pop-
ulation develops limited ¢lamentous tau pathology
with ageing [88]. The new work has ¢rmly estab-
lished that the events leading to a ¢lamentous tau
pathology or the mere presence of tau ¢laments are
su⁄cient for the degeneration of a¡ected nerve cells
and glial cells and the onset of dementia. This had
long been suspected to be the case, largely because of
the good correlation between neuro¢brillary lesions
and nerve cell degeneration in Alzheimer’s disease
[89].
The ¢ndings in FTDP-17 may shed light on the
mechanisms that lead to the ¢lamentous tau pathol-
ogy of Alzheimer’s disease. Seattle family A has
shown that the V337M mutation in the third micro-
tubule-binding domain of tau is su⁄cient to lead to a
tau pathology that is indistinguishable from that of
Alzheimer’s disease in its ultrastructural and bio-
chemical characteristics [15]. As in Alzheimer’s dis-
ease, the tau ¢laments are PHFs and SFs that consist
of all six tau isoforms. The proportion of PHFs (90^
95%) to SFs (5^10%) in Seattle family A is also iden-
tical to that found in Alzheimer’s disease. It suggests
that in Alzheimer’s disease a reduced ability of tau to
interact with microtubules may also be upstream of
hyperphosphorylation and ¢lament assembly.
The presence of mutations in the amyloid precur-
sor protein (APP) gene in about 30 families with
early-onset Alzheimer’s disease has revealed a genetic
lesion that leads to a ¢lamentous tau pathology, as
has the larger number of families with mutations in
the presenilin genes [90,91]. In these families, tau
pathology must be downstream of APP and preseni-
lin dysfunction, but it may be the tau pathology that
eventually causes neurodegeneration. The various
FTDP-17 families now show that primary lesions in
tau itself lead to neurodegeneration. It remains to be
seen whether one can generalise from these familial
cases to the 20^25 million cases of sporadic Alzheim-
er’s disease.
Filamentous tau deposits are also the de¢ning neu-
ropathological characteristic of neurodegenerative
diseases that have been subsumed under the heading
of a ‘Pick complex’ [66,92]. They include progressive
supranuclear palsy (PSP), corticobasal degeneration
(CBD), Pick’s disease and several other diseases. The
tau pathology of PSP and CBD bears a striking re-
semblance to that of cases of FTDP-17 with muta-
tions that destabilise the exon 10 splicing regulatory
element RNA. Thus, ¢lamentous tau deposits are
present in both nerve cells and glial cells [93]. More-
over, tau ¢laments are either straight or have the
appearance of twisted ribbons, and consist of only
four-repeat isoforms [94,95]. The similarities with
FTDP-17 suggest that PSP and CBD may be exon
10 splicing diseases that are caused by an overpro-
duction of four-repeat tau isoforms.
Although PSP is usually sporadic, several case-
control studies have shown a genetic association be-
tween PSP and a GT dinucleotide polymorphism lo-
cated in the intron between exons 9 and 10 of the tau
gene [96^101]. In healthy Caucasians, approximately
50% of subjects are homozygous for the a0 allele
(with 11 GT repeats). This ¢gure is approximately
95% for patients with PSP. The known alleles are
thought to be in linkage disequilibrium with the dis-
ease locus that is believed to be the tau gene. Muta-
tions within additional, as yet unknown tau exon 10
splicing regulatory elements may thus well predispose
to PSP. Two extended haplotypes covering the tau
gene have been described in Caucasians [100]. The
more common haplotype H1 is over-represented in
patients with PSP, re£ecting the association of the a0
allele with that haplotype. With respect to the iso-
form composition of tau ¢laments, Pick’s disease is
the opposite of PSP and CBD. It is characterised by
¢laments that are made of tau isoforms with three
microtubule-binding repeats [102,103]. Although
most cases of Pick’s disease are thought to be spora-
dic, mutations that lead to reduced splicing in of
exon 10 could predispose to Pick’s disease.
The emerging picture is one where FTDP-17, PSP,
CBD and Pick’s disease are all primary tauopathies.
On clinical grounds, the P301S mutation in tau leads
to either frontotemporal dementia or CBD in di¡er-
ent members of the same family, indicating that ge-
netic background can in£uence clinical presentation
[29].
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